Striking study results last year indicated a new type of medicine may improve on Merck’s immunotherapy, spurring a wave of ...

The closing of the merger is expected to occur as soon as practicable, subject to the satisfaction or waiver of the remaining customary closing conditions. Following the closing of the merger, the ...

Continuous administration of ranibizumab with a port delivery system provides an alternative to frequent intravitreal ...

Additionally, the prognosis of macular edema may help clinicians evaluate renal function, investigators reported ...

D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and ...

New anti–vascular endothelial growth factor (VEGF) therapies are improving retinal disease management by providing patients ...

Older patients with diabetic macular edema have a weaker response to anti-VEGF treatment, according to a presentation at ...

DUBLIN--(BUSINESS WIRE)--The "PD-1 x VEGF and PD-L1 x VEGF Bispecific Antibodies: A Business, Pipeline And Competitor Analysis From An Industry Perspective" report has been added to ...

Physicians’ Education Resource (PER ®) is excited to announce the launch of Retina Resource, a comprehensive source of cutting-edge education and information on the latest innovations in anti-VEGF ...